Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer

Parichart Naruphontjirakul,1 Kwanchanok Viravaidya-Pasuwat1,21Biological Engineering Program, Faculty of Engineering, King Mongkut’s University of Technology Thonburi, Bangkok, Thailand; 2Department of Chemical Engineering, Faculty of Engineering, King Mongkut’s University of Tec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Naruphontjirakul P, Viravaidya-Pasuwat K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Pluronic grafted chitosan core-shell nanoparticles doxorubicin anti-HER2 MCF-7 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e14f08e3fa7345429becd538c80dd2b7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e14f08e3fa7345429becd538c80dd2b7
record_format	dspace
spelling	oai:doaj.org-article:e14f08e3fa7345429becd538c80dd2b72021-12-02T08:04:43ZDevelopment of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer1178-2013https://doaj.org/article/e14f08e3fa7345429becd538c80dd2b72019-06-01T00:00:00Zhttps://www.dovepress.com/development-of-anti-her2-targeted-doxorubicin-core-shell-chitosan-nano-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Parichart Naruphontjirakul,1 Kwanchanok Viravaidya-Pasuwat1,21Biological Engineering Program, Faculty of Engineering, King Mongkut’s University of Technology Thonburi, Bangkok, Thailand; 2Department of Chemical Engineering, Faculty of Engineering, King Mongkut’s University of Technology Thonburi, Bangkok, ThailandPurpose: Doxorubicin (DOX) encapsulated O-succinyl chitosan graft Pluronic® F127 (OCP) copolymer nanoparticles conjugated with an anti-HER2 monoclonal antibody were developed as targeted drug delivery vehicles for the treatment of HER2-overexpressing breast cancer.Methods: Five percent and 10% (w/w) of O-succinyl chitosan was grafted onto Pluronic® F127 using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) as mediated cross-linking agents. DOX was added to the copolymer solution to form DOX-nanoparticles before conjugation with anti-HER2 on the surface of the nanoparticles.Results: DOX was encapsulated within the NP matrices at an encapsulation efficiency of 73.69 ± 0.53% to 74.65 ± 0.44% (the initial DOX concentration was 5 μg/mL). Anti-HER2 was successfully conjugated onto the surface of the nanoparticles at a moderately high conjugation efficiency of approximately 57.23 ± 0.38% to 61.20 ± 4.42%. In the in vitro DOX dissolution study, the nanoparticle formulations exhibited a biphasic drug release with an initial burst release followed by a sustained release proﬁle at both pH 5.0 and pH 7.4. The drug was rapidly and completely released from the nanoparticles at pH 5.0. In the in vitro cytotoxicity, the anti-HER2 conjugated OCP copolymer nanoparticles showed the lowest IC50, which indicated an increase in the therapeutic efficacy of DOX to treat human breast cancer cells with the HER2 overexpression.Conclusion: Our study shows that anti-HER2 conjugated OCP copolymer nanoparticles have the potential for the development of anticancer drug carriers.Keywords: pluronic grafted chitosan, core-shell nanoparticles, doxorubicin, anti-HER2, MCF-7Naruphontjirakul PViravaidya-Pasuwat KDove Medical PressarticlePluronic grafted chitosancore-shell nanoparticlesdoxorubicinanti-HER2MCF-7Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 4105-4121 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pluronic grafted chitosan core-shell nanoparticles doxorubicin anti-HER2 MCF-7 Medicine (General) R5-920
spellingShingle	Pluronic grafted chitosan core-shell nanoparticles doxorubicin anti-HER2 MCF-7 Medicine (General) R5-920 Naruphontjirakul P Viravaidya-Pasuwat K Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
description	Parichart Naruphontjirakul,1 Kwanchanok Viravaidya-Pasuwat1,21Biological Engineering Program, Faculty of Engineering, King Mongkut’s University of Technology Thonburi, Bangkok, Thailand; 2Department of Chemical Engineering, Faculty of Engineering, King Mongkut’s University of Technology Thonburi, Bangkok, ThailandPurpose: Doxorubicin (DOX) encapsulated O-succinyl chitosan graft Pluronic® F127 (OCP) copolymer nanoparticles conjugated with an anti-HER2 monoclonal antibody were developed as targeted drug delivery vehicles for the treatment of HER2-overexpressing breast cancer.Methods: Five percent and 10% (w/w) of O-succinyl chitosan was grafted onto Pluronic® F127 using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) as mediated cross-linking agents. DOX was added to the copolymer solution to form DOX-nanoparticles before conjugation with anti-HER2 on the surface of the nanoparticles.Results: DOX was encapsulated within the NP matrices at an encapsulation efficiency of 73.69 ± 0.53% to 74.65 ± 0.44% (the initial DOX concentration was 5 μg/mL). Anti-HER2 was successfully conjugated onto the surface of the nanoparticles at a moderately high conjugation efficiency of approximately 57.23 ± 0.38% to 61.20 ± 4.42%. In the in vitro DOX dissolution study, the nanoparticle formulations exhibited a biphasic drug release with an initial burst release followed by a sustained release proﬁle at both pH 5.0 and pH 7.4. The drug was rapidly and completely released from the nanoparticles at pH 5.0. In the in vitro cytotoxicity, the anti-HER2 conjugated OCP copolymer nanoparticles showed the lowest IC50, which indicated an increase in the therapeutic efficacy of DOX to treat human breast cancer cells with the HER2 overexpression.Conclusion: Our study shows that anti-HER2 conjugated OCP copolymer nanoparticles have the potential for the development of anticancer drug carriers.Keywords: pluronic grafted chitosan, core-shell nanoparticles, doxorubicin, anti-HER2, MCF-7
format	article
author	Naruphontjirakul P Viravaidya-Pasuwat K
author_facet	Naruphontjirakul P Viravaidya-Pasuwat K
author_sort	Naruphontjirakul P
title	Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
title_short	Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
title_full	Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
title_fullStr	Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
title_full_unstemmed	Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
title_sort	development of anti-her2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/e14f08e3fa7345429becd538c80dd2b7
work_keys_str_mv	AT naruphontjirakulp developmentofantiher2targeteddoxorubicinndashcoreshellchitosannanoparticlesforthetreatmentofhumanbreastcancer AT viravaidyapasuwatk developmentofantiher2targeteddoxorubicinndashcoreshellchitosannanoparticlesforthetreatmentofhumanbreastcancer
_version_	1718398696039645184

Development of anti-HER2-targeted doxorubicin&ndash;core-shell chitosan nanoparticles for the treatment of human breast cancer

Ejemplares similares

Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer